One genotype, many phenotypes: SDHB p.R90X mutation-associated paragangliomas
- PMID: 32804377
- DOI: 10.1007/s12020-020-02461-8
One genotype, many phenotypes: SDHB p.R90X mutation-associated paragangliomas
Abstract
Context: SDHB p.R90X germline mutation is the most common genetic alteration in our patients with familial or apparently sporadic pheochromocytoma/paraganglioma (PPGL).
Objective: To analyze the clinical and pathological characteristics, response to therapy, and outcome of patients with SDHB p.R90X-associated PPGL and describe the clinical phenotypic variability in the patients carrying this mutation.
Methods: We reviewed the clinical and pathological characteristics and analyzed the phenotypic variability of all 13 patients that have SDHB p.R90X mutation-associated PPGL.
Results: Thirteen patients (five females and eight males). The median age at diagnosis was 23 years (range 8-43). Although the mutation was the same, there was significant phenotypic variability between patients and even within the same family. Four patients (30.8%) had a family history of PPGL and six patients (46%) had distant metastasis. Surgery of the primary tumor was performed in 11 patients (84.6%). Two patients had inoperable PPGL. Patients with metastasis received different combinations of chemotherapy, Lu177 radiotherapy, multikinase inhibitors, and external irradiation. Only five patients (38.5%) were in remission at a follow-up duration of 4-9 years. The other patients either died due to their disease progression (four patients, 30.8%) or continue to have progressive disease (two patients, 15.4%) or recurrence (one patient, 7.7%). Patients with distant metastasis were older, had larger primary tumors, were more likely to have a family history of PPGL and had a worse outcome.
Conclusion: SDHB p.R90X mutation-associated PPGL have significant phenotypic variability and are associated with a high risk of distant metastasis and mortality.
Keywords: Genotype; Mutation; Paraganglioma; Phenotype; SDHB; SDHx.
Similar articles
-
Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers: a systematic review and updated meta-analysis.J Med Genet. 2020 Apr;57(4):217-225. doi: 10.1136/jmedgenet-2019-106324. Epub 2019 Oct 24. J Med Genet. 2020. PMID: 31649053
-
Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.Clin Genet. 2014 Nov;86(5):482-6. doi: 10.1111/cge.12304. Epub 2013 Nov 15. Clin Genet. 2014. PMID: 24134185
-
Germline Mutations and Phenotypic Associations in Korean Patients With Pheochromocytoma and Paraganglioma: A Multicenter Study and Literature Review.Ann Lab Med. 2024 Nov 1;44(6):591-597. doi: 10.3343/alm.2023.0376. Epub 2024 Jul 29. Ann Lab Med. 2024. PMID: 39069753 Free PMC article. Review.
-
Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.J Clin Endocrinol Metab. 2022 Sep 28;107(10):2801-2810. doi: 10.1210/clinem/dgac474. J Clin Endocrinol Metab. 2022. PMID: 35948272
-
An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline SDHB pathogenic variant in the absence of paraganglioma or pheochromocytoma.Front Endocrinol (Lausanne). 2023 Dec 13;14:1273093. doi: 10.3389/fendo.2023.1273093. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38152133 Free PMC article.
Cited by
-
Patient Sex and Origin Influence Distribution of Driver Genes and Clinical Presentation of Paraganglioma.J Endocr Soc. 2024 Feb 29;8(5):bvae038. doi: 10.1210/jendso/bvae038. eCollection 2024 Mar 12. J Endocr Soc. 2024. PMID: 38481600 Free PMC article.
References
-
- J.W. Lenders, Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915–1942 (2014) - DOI
-
- Alrezk, R., Suarez, A., Tena, I., Pacak, K. Update of pheochromocytoma syndromes: genetics, biochemical evaluation, and imaging. Front. Endocrinol. 9, 515 (2018). https://doi.org/10.3389/fendo.2018.00515
-
- L. Fishbein, I. Leshchiner, V. Walter, L. Danilova, A.G. Robertson, A.R. Johnson, T.M. Lichtenberg, B.A. Murray, H.K. Ghayee, T. Else, S. Ling, S.R. Jefferys, A.A. de Cubas, B. Wenz, E. Korpershoek, A.L. Amelio, L. Makowski, W.K. Rathmell, A.P. Gimenez-Roqueplo, T.J. Giordano, S.L. Asa, A.S. Tischler; Cancer Genome Atlas Research, N., K. Pacak, K.L. Nathanson, M.D. Wilkerson, Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31(2), 181–193 (2017). https://doi.org/10.1016/j.ccell.2017.01.001 - DOI - PubMed - PMC
-
- R.G. Dluhy, Pheochromocytoma-death of an axiom. N. Engl. J. Med. 346(19), 1486–1488 (2002). https://doi.org/10.1056/nejm200205093461911 - DOI - PubMed
-
- B.E. Baysal, Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287, 848–851 (2000) - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous